CR20120549A - Composiciones farmacèuticas que comprenden hidromorfona y naloxona - Google Patents

Composiciones farmacèuticas que comprenden hidromorfona y naloxona

Info

Publication number
CR20120549A
CR20120549A CR20120549A CR20120549A CR20120549A CR 20120549 A CR20120549 A CR 20120549A CR 20120549 A CR20120549 A CR 20120549A CR 20120549 A CR20120549 A CR 20120549A CR 20120549 A CR20120549 A CR 20120549A
Authority
CR
Costa Rica
Prior art keywords
naloxone
pharmaceutical compositions
include hydromorphone
hydromorphone
humans
Prior art date
Application number
CR20120549A
Other languages
English (en)
Inventor
Helen Kathleen Danagher
Hassan Mohammad
Malcolm Walden
Geoffrey Gerard Hayes
Jonathon Oliver Whitehouse
Thinnayam Naganathan Krishnamurthy
Rincon Ricardo Alberto Vargas
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42983574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120549(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of CR20120549A publication Critical patent/CR20120549A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas de dosis farmacéuticas de liberación prolongada, la preparación de las mismas, así como también su uso para administrar a seres humanos.
CR20120549A 2010-05-10 2012-10-29 Composiciones farmacèuticas que comprenden hidromorfona y naloxona CR20120549A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10162428 2010-05-10

Publications (1)

Publication Number Publication Date
CR20120549A true CR20120549A (es) 2013-03-08

Family

ID=42983574

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120549A CR20120549A (es) 2010-05-10 2012-10-29 Composiciones farmacèuticas que comprenden hidromorfona y naloxona

Country Status (35)

Country Link
US (1) US9700508B2 (es)
EP (1) EP2568967B2 (es)
JP (1) JP5671609B2 (es)
KR (2) KR101858797B1 (es)
CN (2) CN102946870A (es)
AP (1) AP3441A (es)
AR (1) AR083150A1 (es)
AU (1) AU2011252039B2 (es)
BR (1) BR112012028773A2 (es)
CA (1) CA2739751C (es)
CH (1) CH705273B1 (es)
CL (1) CL2012003012A1 (es)
CO (1) CO6640216A2 (es)
CR (1) CR20120549A (es)
DE (1) DE112011101605T5 (es)
DK (1) DK178741B1 (es)
EA (1) EA201291211A1 (es)
EC (1) ECSP12012236A (es)
ES (1) ES2408343B2 (es)
GB (1) GB2492037A (es)
GT (1) GT201200304A (es)
IL (1) IL222772B (es)
MX (1) MX347105B (es)
MY (1) MY157673A (es)
NI (1) NI201200157A (es)
NO (1) NO20121414A1 (es)
NZ (2) NZ700732A (es)
PE (1) PE20130657A1 (es)
SE (1) SE1251371A1 (es)
SG (1) SG184523A1 (es)
TN (1) TN2012000488A1 (es)
TW (2) TWI590835B (es)
UA (1) UA106278C2 (es)
WO (1) WO2011141488A2 (es)
ZA (1) ZA201207603B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
BR112012028656A2 (pt) 2010-05-10 2016-08-09 Euro Celtique Sa combinação de grânulos carregados ativos com ativos adicionais
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
TWI566786B (zh) * 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
CA2881144A1 (en) * 2012-11-09 2014-05-09 Purdue Pharma Pharmaceutical compositions comprising hydromorphone and naloxone
US9517208B2 (en) * 2013-03-15 2016-12-13 Purdue Pharma L.P. Abuse-deterrent dosage forms
GB201313915D0 (en) * 2013-08-02 2013-09-18 Johnson Matthey Plc Process
BR112016009749A8 (pt) * 2013-11-13 2018-01-30 Euro Celtique Sa hidromorfona e naloxona para tratamento de dor e síndrome de disfunção intestinal opioide
CA2847781C (en) * 2014-03-28 2019-03-12 Purdue Pharma Reducing drug liking in a subject
EP3229785A2 (de) * 2014-12-08 2017-10-18 Develco Pharma Schweiz AG Naloxon-monopräparat und mehrschichttablette
CA3164723A1 (en) * 2020-02-14 2021-08-19 Jutaro Shudo Topical naloxone compositions and methods for using the same

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE49324B1 (en) 1979-12-19 1985-09-18 Euro Celtique Sa Controlled release compositions
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
HU190619B (en) 1983-11-11 1986-09-29 Bezzegh,Denes,Hu Process for producing tablets with controlled dissolution of active ingredients
EP0164669B1 (de) 1984-06-13 1991-01-23 Röhm Gmbh Verfahren zum Überziehen von Arzneiformen
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
GB8626098D0 (en) 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
EP0352361A1 (en) 1988-07-29 1990-01-31 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE4443105C2 (de) 1994-12-03 1997-03-13 Hoechst Ag Verfahren zur Herstellung Molsidomin-haltiger Tabletten
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
ATE322892T1 (de) 1997-07-02 2006-04-15 Euro Celtique Sa Stabilisierte tramadol formulierungen mit verzögerter freisetzung
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
ECSP003314A (es) 2000-01-11 2000-03-22 Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide y un - agonista
PT1255547E (pt) * 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
CN1592609A (zh) * 2001-05-11 2005-03-09 恩德制药公司 抗滥用阿片样物质剂型
EP1392250A2 (en) 2001-06-08 2004-03-03 Endo Pharmaceuticals Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
PL367427A1 (en) * 2001-08-06 2005-02-21 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
HUP0401195A3 (en) 2001-08-06 2006-11-28 Euro Celtique Sa Compositions to prevent abuse of opioids containing aversive agent and process of their preparation
US7332182B2 (en) * 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7435817B2 (en) 2001-08-23 2008-10-14 N.V. Organon C-14 oxidation of morphine derivatives
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
MXPA04009713A (es) 2002-04-05 2005-01-11 Euro Celtique Sa Preparacion farmaceutica que contiene oxicodona y naloxona.
DE10215131A1 (de) * 2002-04-05 2003-10-16 Euro Celtique Sa Matrix zur verzögerten, gleichbleibenden und unabhängigen Freisetzung von Wirkstoffen
AU2003246351B2 (en) 2002-07-04 2009-02-19 Janssen Pharmaceutica N.V. Solid dispersions comprising two different polymer matrixes
PT1615646E (pt) 2003-04-08 2015-02-12 Progenics Pharm Inc Formulações farmacêuticas com metilnaltrexona
WO2004091622A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome
MXPA05010821A (es) 2003-04-08 2006-03-30 Progenics Pharm Inc Terapia de combinacion para constipacion que comprende un laxante y un antagonista opioide periferico.
EP1641441B1 (en) 2003-04-30 2014-03-12 Purdue Pharma L.P. Tamper-resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
US9114199B2 (en) 2003-07-31 2015-08-25 Boston Scientific Scimed, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050079221A1 (en) 2003-10-10 2005-04-14 Groenewoud Pieter Jurjen Ibuprofen narcotic composition and method for making same
US20050232987A1 (en) 2004-03-12 2005-10-20 Viswanathan Srinivasan Dosage form containing a morphine derivative and another drug
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
ATE451374T1 (de) 2004-02-06 2009-12-15 Euro Celtique Sa Verfahren zur herstellung 3-o-geschützter morphinone und 3-o-geschützter morphinon-dienol- carboxylate
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US7700626B2 (en) 2004-06-04 2010-04-20 Adolor Corporation Compositions containing opioid antagonists
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
US20060088594A1 (en) 2004-10-08 2006-04-27 Pilgaonkar Pratibha S Highly compressible controlled delivery compositions of metformin
GB0423103D0 (en) 2004-10-19 2004-11-17 Boots Healthcare Int Ltd Therapeutic agents
JP2008528497A (ja) 2005-01-20 2008-07-31 プロジェニックス ファーマシューティカルズ，インコーポレーテッド メチルナルトレキソンおよび関連化合物の術後性胃腸障害のための使用
EP2319499A1 (en) * 2005-01-28 2011-05-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1695700A1 (en) 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
NL1028460C2 (nl) * 2005-03-04 2006-09-06 Sara Lee De Nv Inrichting voor het bereiden en afgeven van al dan niet althans gedeeltelijk opgeschuimde dranken.
JP4741865B2 (ja) 2005-03-24 2011-08-10 共和薬品工業株式会社 ペルゴリド錠剤の製造方法
US20070026025A1 (en) 2005-04-12 2007-02-01 Aquegel Cosmetics, Llc Topical ointment and method for making and using same
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070059360A1 (en) 2005-07-29 2007-03-15 Ashish Jaiswal Water-dispersible anti-retroviral pharmaceutical compositions
US20070048364A1 (en) 2005-08-04 2007-03-01 Yingxu Peng Free flowing granules containing carbomer
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
WO2007068615A2 (en) 2005-12-14 2007-06-21 F. Hoffmann-La Roche Ag Hcv prodrug formulation
US20070141147A1 (en) 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
EP1813276A1 (en) 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US7799790B2 (en) 2006-07-20 2010-09-21 Helm Ag Amorphous aripiprazole and process for the preparation thereof
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102006051020A1 (de) 2006-10-26 2008-04-30 Evonik Röhm Gmbh Verwendung von (Meth)acrylat-Copolymeren in Retard-Arzneiformen zur Verringerung des Einflusses von Ethanol auf die Wirkstofffreisetzung
GB2447898B (en) 2007-03-24 2011-08-17 Reckitt Benckiser Healthcare A tablet having improved stability with at least two actives
PT2379066E (pt) 2008-09-16 2014-07-04 Imuneks Farma Ilaç Sanayi Ve Ticaret A S Uso de antagonistas opioides para a preparação de um medicamento no tratamento das doenças degenerativas da retina
CN102159193B (zh) 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
PL2326313T3 (pl) 2008-09-24 2015-08-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
CN102164588B (zh) 2008-09-24 2015-07-08 赢创罗姆有限公司 耐受乙醇影响的pH依赖性受控释放的药物组合物
PE20142368A1 (es) 2008-10-30 2015-02-04 Gruenenthal Chemie Formas de dosificacion del tapentadol novedosas y potentes
US20100143486A1 (en) 2008-12-10 2010-06-10 Nipun Davar Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
US8362029B2 (en) 2008-12-31 2013-01-29 Upsher-Smith Laboratories, Inc. Opioid-containing oral pharmaceutical compositions and methods
EP2385943A4 (en) 2009-01-09 2012-05-30 Harvard College FLUORINATED COMPOUNDS AND METHODS OF USE
EP2389159A1 (en) 2009-01-22 2011-11-30 Noramco, Inc. Process for preparing particles of opioids and compositions produced thereby
CA2751627A1 (en) 2009-02-06 2010-08-12 Egalet Ltd. Pharmaceutical compositions resistant to abuse
PL2398808T3 (pl) 2009-02-17 2014-04-30 Mallinckrodt Llc Sposób redukcyjnego alkilowania normorfinanów
EP2398806A1 (en) 2009-02-23 2011-12-28 Mallinckrodt LLC (+)-morphinanium n-oxides and processes for their production
CN102325776A (zh) 2009-02-23 2012-01-18 马林克罗特公司 (+)-吗啡喃*季盐及其制备方法
US20100227876A1 (en) 2009-03-06 2010-09-09 Rechfensen Llp Methods of Reducing Side Effects of Analgesics
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20110311631A1 (en) 2009-03-18 2011-12-22 Evonik Röhm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising a polymer mixture and excipients
CA2755808C (en) 2009-03-18 2016-01-19 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN102573845A (zh) 2009-04-02 2012-07-11 夏尔有限责任公司 新的阿片样物质的二羧酸连接的氨基酸和肽前药及其用途
WO2010120232A1 (en) 2009-04-14 2010-10-21 Yki, Ytkemiska Institutet Ab A prodrug comprising beta-keto carboxylic acid, beta-keto carboxylic acid salt or beta-keto carboxylic acid ester for drug delivery
US20100291151A1 (en) 2009-04-21 2010-11-18 Auspex Pharmaceuticals, Inc. 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor
RU2530655C2 (ru) 2009-04-24 2014-10-10 Омиа Интернэшнл Аг Материал в виде частиц для контролируемого высвобождения активных ингредиентов
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2764915C (en) 2009-06-11 2017-07-11 Mallinckrodt Llc Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
AR077420A1 (es) 2009-07-22 2011-08-24 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion para opiaceos sensibles a la oxidacion
EP2456427B1 (en) 2009-07-22 2015-03-04 Grünenthal GmbH Hot-melt extruded controlled release dosage form
GB0914338D0 (en) 2009-08-17 2009-09-30 Johnson Matthey Plc Improved process
BR112012005124B1 (pt) 2009-09-08 2021-11-09 Signature Therapeutics, Inc. Pro-fármaco de opioide modificado por cetona, seu método de preparação, sua composição farmacêutica, sua unidade de dose, métodos e usos
EP3064064A1 (en) 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
WO2011041470A2 (en) 2009-09-30 2011-04-07 Mallinckrodt Inc. Sustained-release opiate and opiate derivative compositions
BR112012028656A2 (pt) 2010-05-10 2016-08-09 Euro Celtique Sa combinação de grânulos carregados ativos com ativos adicionais
AU2011252040C1 (en) 2010-05-10 2015-04-02 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
GB201020895D0 (en) 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form

Also Published As

Publication number Publication date
GT201200304A (es) 2014-06-09
IL222772B (en) 2018-11-29
WO2011141488A2 (en) 2011-11-17
UA106278C2 (uk) 2014-08-11
US20130178492A1 (en) 2013-07-11
TN2012000488A1 (en) 2014-04-01
ES2408343R1 (es) 2013-08-28
KR20150028367A (ko) 2015-03-13
EP2568967B1 (en) 2018-10-24
MX347105B (es) 2017-04-12
CN105832687A (zh) 2016-08-10
TWI483748B (zh) 2015-05-11
TW201503913A (zh) 2015-02-01
KR20130030260A (ko) 2013-03-26
NZ700732A (en) 2015-08-28
US9700508B2 (en) 2017-07-11
TWI590835B (zh) 2017-07-11
CA2739751A1 (en) 2011-11-10
EA201291211A1 (ru) 2013-05-30
JP2013526508A (ja) 2013-06-24
ECSP12012236A (es) 2013-02-28
PE20130657A1 (es) 2013-06-15
CO6640216A2 (es) 2013-03-22
NI201200157A (es) 2013-02-05
DK201270677A (en) 2012-11-05
ES2408343B2 (es) 2014-07-17
AU2011252039B2 (en) 2014-06-12
BR112012028773A2 (pt) 2016-07-19
DE112011101605T5 (de) 2013-04-25
IL222772A0 (en) 2012-12-31
CN102946870A (zh) 2013-02-27
GB2492037A (en) 2012-12-19
AR083150A1 (es) 2013-02-06
GB201219275D0 (en) 2012-12-12
TW201206501A (en) 2012-02-16
AP3441A (en) 2015-10-31
CA2739751C (en) 2014-08-12
AU2011252039A1 (en) 2012-11-08
CL2012003012A1 (es) 2014-02-21
KR101858797B1 (ko) 2018-05-16
MX2012013119A (es) 2013-02-11
ZA201207603B (en) 2014-12-23
SE1251371A1 (sv) 2012-12-27
DK178741B1 (da) 2016-12-19
EP2568967A2 (en) 2013-03-20
NO20121414A1 (no) 2013-02-11
MY157673A (en) 2016-07-15
WO2011141488A3 (en) 2012-04-05
JP5671609B2 (ja) 2015-02-18
CH705273B1 (de) 2016-06-15
SG184523A1 (en) 2012-11-29
ES2408343A2 (es) 2013-06-20
NZ603497A (en) 2015-02-27
AP2012006606A0 (en) 2012-12-31
EP2568967B2 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
CR20120549A (es) Composiciones farmacèuticas que comprenden hidromorfona y naloxona
DOP2012000279A (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
CR20130033A (es) Formulaciones de rifaximina y usos de las mismas
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CR20150326A (es) Inhibidores de autotaxina
BR112015010663A8 (pt) formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
CO6640305A2 (es) Elaboración de gránulos sin activos y tabletas que comprenden los mismos
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
UY31922A (es) Compuestos
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
PE20150353A1 (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales
BR112015025781A2 (pt) composição farmacêutica para uso inalatório e kit para a administração de um fármaco como um pó inalatório
BR112014008588A2 (pt) derivados de 2-oxo-piperidinila
CL2015000778A1 (es) Composición farmacéutica oral sinérgica que comprende nitazoxanida y mebendazol; proceso de preparación; y uso para el tratar parasitosis humana provocada por protozoos y helmintos.
CL2015000310A1 (es) Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg.
NI201200162A (es) Inhibidores de pirazolil quinoxalina cinasa
BR112015029693A8 (pt) formulação farmacêutica de um inibidor de hif hidroxilase, forma de dosagem sólida compreendendo a referida formulação e método para inibir a fotodegradação de ácido
BR112014032037A2 (pt) formulações para a preparação de comprimidos de liberação imediata para uso oral contendo uma baixa dosagem de mifepristona para o tratamento de endometriose, comprimidos desse modo obtidos e seu processo de preparação